Utah Medical Products (UTMD) Liabilities and Shareholders Equity (2010 - 2026)

Utah Medical Products' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $124.4 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 1.52% year-over-year to $124.4 million in Q1 2026; TTM through Mar 2026 was $489.7 million, a 2.99% decrease from a year earlier, with the FY2025 full-year figure at $122.5 million, changed 0.0% from the prior year.
• Liabilities and Shareholders Equity rose to $124.4 million in Q1 2026 per UTMD's latest filing, from $122.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $135.5 million in Q4 2023 and bottomed at $116.1 million in Q2 2022.
• The 5-year median for Liabilities and Shareholders Equity is $123.9 million (2022), against an average of $125.5 million.
• Across the five-year window, Liabilities and Shareholders Equity increased 12.33% in 2023 and slipped 9.54% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $123.9 million in 2022, then climbed by 9.35% to $135.5 million in 2023, then decreased by 9.54% to $122.5 million in 2024, then climbed by 0.0% to $122.5 million in 2025, then rose by 1.5% to $124.4 million in 2026.
• Per Business Quant, the three latest UTMD Liabilities and Shareholders Equity figures stand at $124.4 million (Q1 2026), $122.5 million (Q4 2025), and $122.0 million (Q3 2025).